natgillin/translations-raw huggingface dataset:
The use according to the preceding claims 3 or 4, wherein a measured level of expression of said miR-124 into an isolated biological sample in presence of said candidate compared to a control reference value, and wherein a modulation of said measured level relative to said control reference value is indicative of the biological effect of said candidate, and in particular of the efficacy of said drug candidate or vaccine candidate in preventing and/or treating a viral infection. 
Uporaba prema prethodnim zahtjevima 3 ili 4, naznačena time što se mjeri razina ekspresije navedene miR-124 u izoliranom biološkom uzorku u prisutnosti navedenog kandidata u usporedbi s kontrolnom referentnom vrijednošću, te pri čemu je modulacija navedene izmjerene razine u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za biološki učinak navedenog kandidata, te naročito djelotvornosti navedenog kandidata za lijek ili kandidata za cjepivo za prevenciju i/ili liječenje virusne infekcije
The use according to claims 3 to 6, wherein said drug candidate or vaccine candidate is a quinoline derivative of formula (I): wherein 
Uporaba prema zahtjevima 3 do 6, naznačena time što je navedeni kandidat za lijek ili kandidat za cjepivo derivat kinolina s formulom (I): pri čemu
R" is a hydrogen atom or a (C1-C4) alkyl group, or one of its pharmaceutically acceptable salt. 
R" je vodikov atom ili skupina (C1-C4) alkil, ili jedna od njihovih farmaceutski prihvatljivih soli.
The use according to claims 3 to 6, wherein said drug candidate or vaccine candidate is a quinoline derivative of formula (II): wherein 
Uporaba prema zahtjevima 3 do 6, naznačena time što navedeni kandidat za lijek ili kandidat za cjepivo je derivat kinolina s formulom (II): pri čemu
wherein a modulated presence or level of expression of said miRNA relative to said control reference value is indicative of a viral infection. An in vitro or ex vivo method of assessing an activity of a quinoline derivative according to anyone of claims 9 or 10 for preventing and/or treating a viral infection in a patient treated with said quinoline derivative, comprising at least the steps of: a- measuring a presence or an expression level of at least one miRNA, said at least one miRNA being miR-124, in a first biological sample previously obtained from said patient before administering said quinoline derivative and in a second biological sample previously obtained from said patient after administering said quinoline derivative; and 
In vitro ili ex vivo postupak procjenjivanja virusne infekcije kod pacijenta za kojeg se pretpostavlja da je zaražen virusom, naznačen time što sadrži barem korake: a- mjerenje u biološkom uzorku prethodno dobivenom od navedenog pacijenta prisutnosti ili razine ekspresije barem jedne miRNA, navedena barem jedna miRNA je miR-124; i b- uspoređivanje navedene prisutnosti ili razine ekspresije s kontrolnom referentnom vrijednošću, pri čemu je modulirana prisutnost ili razina ekspresije navedene miRNA u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za virusnu infekciju.
The use according to claim 15, wherein said nucleic acid probe consists in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 87. 
Uporaba prema zahtjevu 15, naznačena time što se navedena sonda nukleinske kiseline sastoji od sekvence nukleinske kiseline odabrane iz skupine koju čine SEQ ID NO: 6 do SEQ ID NO: 87.
The compound for use according to claim 1, wherein the compound is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time što je spoj odabran iz skupine koja se sastoji od: ili njegova farmaceutski prihvatljiva sol.
A compound for use according to any one of claims 13-14, wherein the cancer is selected from the group consisting of neuroblastoma, ovarian cancer, colorectal cancer, melanoma, head and neck cancer, gastric cancer, gastric carcinoma, lung carcinoma, breast cancer, glioblastoma, medulloblastoma, secretory breast cancer, salivary gland cancer, papillary thyroid carcinoma, adult myeloid leukemia, pancreatic cancer, and prostate cancer. 
Spoj za uporabu prema zahtjevu 16, naznačen time što je rak odabran iz skupine koju čine: neuroblastoma, karcinom jajnika, gušterače, kolorektalni karcinom, karcinom prostate, melanom, rak glave i vrata, karcinom želuca, karcinom pluća, rak dojke, glioblastom, meduloblastom, sekretorni karcinom dojke, rak žlijezda slinovnica, i papilarni karcinom štitnjače.
introducing a solid raw material mix comprising 40 to 100 w% of man-made mineral fibers into a submerged combustion melter; 
– unosa mješavine čvrstih sirovina koja sadrži 40 do 100 %, težinski, umjetnih mineralnih vlakana u talionik s uronjenim izgaranjem;
melting the solid raw material mix in the submerged combustion melter to form a liquid melt; 
– taljenja mješavine čvrstih sirovina u talioniku s uronjenim izgaranjem kako bi se dobilo tekuću talinu;
Process according to claim 1 in which the process is carried out in the absence of additional separate oxygen or oxygen enriched air injection into the melter. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se postupak provodi u odsutnosti dodatnog odvojenog injiciranja kisika ili zraka obogaćenog kisikom u talionik.
Process according to any of claims 1 to 3 in which the step of forming the withdrawn liquid melt into a solid vitrified material comprises fiberizing the liquid melt to produce mineral wool fibers, notably glass wool fibers or stone wool fibers. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što korak oblikovanja izvučene tekuće taline u čvrsti vitrificirani materijal sadrži pretvaranje tekuće taline u vlakna kako bi se dobilo vlakna mineralne vune, osobito vlakna staklene vune ili vlakna kamene vune.
Process according to any of claims 1 to 4 in which the man-made mineral fibers of the solid raw material mix are selected from glass fibers, glass wool fibers, stone wool fibers and combinations thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se umjetna mineralna vlakna od mješavine čvrstih sirovina bira između staklenih vlakana, vlakana staklene vune, vlakana kamene vune i njihovih kombinacija.
Process according to any of claims 1 to 5 in which the step of melting the solid raw material mix in the submerged combustion melter comprises generating a substantially toroidal melt flow pattern in the melt, having a substantially vertical central axis of revolution, comprising major centrally inwardly convergent flows at the melt surface. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se korak taljenja mješavine čvrstih sirovina u talioniku s uronjenim izgaranjem sastoji u postizanju uglavnom toroidnog uzorka toka taline u talini, koji ima uglavnom okomitu središnju os kruženja, koji se sastoji od glavnih tokova koji konvergiraju prema središtu na površini taline.
Process according to claim 7 in which the fluid dynamics model is code ANSYS R14.5, taking into consideration the multi-phase flow field ranging from solid batch material to liquid melt and gas generated in the course of the conversion, and the batch-to-melt conversion. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je model dinamike fluida kod ANSYS R14.5, koji uzima u obzir višefazno polje toka u rasponu od čvrstog šaržnog materijala do tekuće taline i plina nastalih tijekom pretvorbe, te pretvorbu šarže u talinu.
The process of claim 1 in which the process is carried out in the absence of additional separate oxygen or oxygen enriched air injection into the melter. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se postupak provodi u odsutnosti dodatnog odvojenog injiciranja kisika ili zraka obogaćenog kisikom u talionik.
The process of claim 1 in which the step of forming the withdrawn liquid melt into a solid vitrified material comprises fiberizing the liquid melt to produce mineral wool fibers selected from glass wool fibers and stone wool fibers. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što korak oblikovanja izvučene tekuće taline u čvrsti vitrificirani materijal sadrži pretvaranje tekuće taline u vlakna kako bi se dobilo vlakna mineralne vune, osobito vlakna staklene vune ili vlakna kamene vune.
The process of claim 1 in which the flocks comprise mineral fibers selected from glass fibers, glass wool fibers, stone wool fibers and combinations thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se umjetna mineralna vlakna od mješavine čvrstih sirovina bira između staklenih vlakana, vlakana staklene vune, vlakana kamene vune i njihovih kombinacija.
The process of claim 9 in which the fluid dynamics model is code ANSYS R14.5, taking into consideration the multi-phase flow field ranging from solid batch material to liquid melt and gas generated in the course of the conversion, and the batch-to-melt conversion. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je model dinamike fluida kod ANSYS R14.5, koji uzima u obzir višefazno polje toka u rasponu od čvrstog šaržnog materijala do tekuće taline i plina nastalih tijekom pretvorbe, te pretvorbu šarže u talinu.
The portable mat of claim 1, wherein the base has a first thickness (T3) of approximately 1.27cm (0.5 inches) near an edge of the base and a second thickness (T1) of approximately 1.59 cm (0.625 inches) near a center of the base. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da osnova ima prvu debljinu (T3) od približno 1,27 cm (0,5 palaca) blizu ruba osnove i drugu debljinu (T1) od približno 1,59 cm (0,625 palaca) u blizini središta osnove.
The portable mat of claim 1, wherein the plurality of protrusions (201) vary in height (D1, D2) from a first edge of the base (320) to a second edge of the base (320). 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da više izbočina (201) visinom (D1, D2) variraju od prvog ruba osnove (320) do drugog ruba osnove (320).
The portable mat of claim 1, wherein the thermoplastic elastomer material has a hardness of between 10-150 Shore A on a durometer scale. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da termoplastični elastomerni materijal ima tvrdoću od između 10 - 150 Shore A na ljestvici tvrdoće durometra.
The portable mat of claim 1, further comprising a plurality of pointed protrusions (501) protruding from a second surface (515) of the base (520). 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži više šiljastih izbočina (501) koje strše iz druge plohe (515) osnove (520).
The portable mat of claim 1, wherein the portable mat comprises two separate halves (700, 700'). 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da se prenosivi podložak sastoji od dvije odvojene polovine (700, 700').
The portable mat of claim 10, wherein each half (700) is substantially a mirror image of the other half (700'). 
Prenosivi podložak prema patentnom zahtjevu 10, naznačen time, da je svaka polovina (700) u biti zrcalna slika druge polovine (700').
The portable mat of claim 10, wherein each half (700, 700') is complementary of the other half (700, 700'). 
Prenosivi podložak prema patentnom zahtjevu 10, naznačen time, da je svaka polovina (700, 700') komplementarna drugoj polovini (700, 700').
The portable mat of claim 1, wherein the base has different thicknesses (T2, T3) at opposed outermost edges. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da osnova ima različite debljine (T2, T3) na suprotnim krajnjim vanjskim rubovima.
The portable mat as in claim 1, wherein the base (120) is defined by and bounded by only two straight edges (102a, 102d) intersecting orthogonally and curved edges (102b, 102c) with straight portions joining the two straight edges. A kit (770), characterized by comprising: 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da je osnova (120) određena i omeđena samo s dva ravna ruba (102a, 102d) koji se sijeku pod pravim kutem i sa zakrivljenim rubovima (102b, 102c), čiji se ravni dijelovi spajaju s dva ravna ruba.
a portable mat according to claim 10, and a carrying case for storing and transporting the mat. 
Komplet (770), naznačen time, da sadrži prenosivi podložak prema patentnom zahtjevu 10, te kutiju za spremanje i prenošenje podloška.
The kit of claim 15, wherein the base is monolithically made of a thermoplastic elastomer material. 
Komplet prema patentnom zahtjevu 15, naznačen time, da je osnova monolitno izrađena iz termoplastičnog elastomernog materijala.
Combination according to claim 2 or 3, characterized in that the compound of formula (I) is (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I'), or an acid addition salt thereof, whereby the acid addition salt of hydrochloride is preferred. 
barem jedan antiepileptik odabran iz skupine koja se sastoji od pregabalina i gabapentina, uz uvjet da (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol formule (I') nije tapentadol sa sporim otpuštanjem. Kombinacija prema zahtjevu 1, naznačena time što je kisela adicijska sol hidroklorid.
Combination according to any of claims 1-5, characterized in that components (a) and (b) are present in such a weight ratio that the composition will exert a synergistic effect upon administration to a patient. 
Kombinacija prema bilo kojem od zahtjeva 1-3, naznačena time što su komponente (a) i (b) prisutne u takvom masenom omjeru da sastav pruža sinergistički učinak nakon primjene pacijentu.
An adhesive detergent and/or perfuming and/or sanitizing composition, in gel form, directly applicable to a surface of interest, to which it adheres without the aid of a support and/or a container, and from which, if subjected to the action of flushings of water, is washed away only after a large number of water flushings, said composition being characterized by comprising 
Ljepljiva deterdžentna i/ili mirisna i/ili dezinficirajuća mješavina, u obliku gela, gdje se mješavinu može izravno primijeniti na površinu od interesa, na koju prianja bez pomoći nosača i/ili spremnika, te iz koje, ako se podvrgava djelovanju ispiranja vodom, se ispire samo nakon velikog broja ispiranja vodom, gdje je navedena mješavina naznačena time što sadrži
an adhesion promoter which is ethoxylated hydrogenated castor oil; 
ljepivno pomagalo, koje je etoksilirano hidrogenirano ricinusovo ulje;
iv) optionally a non-ionic surfactant as a detergent/foaming agent; water. 
iv) mogući neionski surfaktant kao deterdžentno/sredstvo za pjenjenje; vodu;
Use of the adhesive composition, in gel, according to any one of the preceding claims, as a detergent and/or perfuming and/or sanitizing agent, by direct application on the surface of interest in lavatory, appliances, walls, furniture. 
Upotreba ljepljive mješavine, u gelu, u skladu s bilo kojim od prethodnih patentnih zahtjeva, kao deterdžentno i/ili mirisno i/ili dezinficirajuće sredstvo, naznačena time što se mješavinu upotrebljava izravnom primjenom na površinu od interesa u nužniku, uređajima, na zidovima, na namještaju.
A process of application of the adhesive composition according to any one of the preceding claims, directly applicable to a surface of interest, to which it adheres without the aid of a support and/or a container. 
Postupak primjene ljepljive mješavine u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se mješavinu može izravno primijeniti na površinu od interesa, na koju prianja bez pomoći nosača i/ili spremnika.
The compound of claim 13, wherein the compound exists in polymorphic form having an XRPD diffraction pattern as indicated in Figure 18. 
Spoj prema patentnom zahtjevu 19 za upotrebu u liječenju shizofrenije, pri čemu spoj postoji u polimorfnom obliku i ima XRPD uzorak difrakcije kako je prikazano na Slici 18.
The compound of any one of claims 1 to 3, or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ⓣ is C3-C6 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein said C3-C6 carcbocyclene is optionally substituted with C1-C4 alkyl or C1-C3 haloalkyl. 
Spoj prema bilo kojem od zahtjeva 1 do 3, ili stereoizomer, ili smjesa stereoizomera, ili njegove farmaceutski prihvatljive soli, gdje je C3-C6 karbociklilen koji je vezan za L i za ostatak spoja formule IV preko dva susjedna ugljika, gdje spomenuti C3-C6 karbociklen je opcionalno supstituiran sa C1-C4 alkil ili C1-C3 haloalkil.
The compound of any one of claims 1 to 3, or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ⓣ is C3-C6 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein the C3-C6 carcbocyclene is optionally substituted with methyl, ethyl or trifluoromethyl. 
Spoj prema bilo kojem od zahtjeva 1 do 3, ili stereoizomer, ili smjesa stereoizomera, ili njegove farmaceutski prihvatljive soli, gdje je C3-C6 karbociklilen koji je vezan za L i za ostatak spoja formule IV preko dva susjedna ugljika, gdje C3-C6 karbociklen je opcionalno supstituiran s metil, etil ili trifluorometil.
The compound of any one of claims 1 to 3, or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ⓣ is C6-C8 bridged bicyclic carbocyclylene or C6-C8 fused bicyclic carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons. 
Spoj prema bilo kojem od zahtjeva 1 do 3, ili stereoizomer, ili smjesa stereoizomera, ili njegove farmaceutski prihvatljive soli, gdje je C6-C8 premošćeni biciklični karbociklilen ili C6-C8 spojeni biciklični karbociklilen koji je vezan za L i za ostatak spoja formule IV preko dva susjedna ugljika.
The pharmaceutical composition of claim 21, further comprising at least one additional therapeutic agent. 
Farmaceutska kompozicija prema zahtjevu 21, dalje sadrži bar jedno dodatno terapeutsko sredstvo.
A valve (100) for administration of two or more drug fluids, such as cytostatics, comprising: 
Ventil (100) za primjenu dva ili više lijekova u obliku tekućina, kao što su, primjerice, citostatici, sadrži:
wherein the valve is arranged such that the valve member (300) can be rotated into: 
gdje je ventil izveden tako da element (300) ventila može biti rotacijom doveden u:
a plurality of drug positions in each of which the single passageway inlet (322) is fluidly connected to a respective one of said drug outlets (208) for guiding an associated drug fluid via a flow path defined by said passageway (320; 321) to said passageway outlet (324), and 
veći broj pozicija za davanje lijekova u svakom od kojih je jedinstveni dovod (322) prolaza u protočnoj vezi s odgovarajućim od navedenih odvoda (208) za lijekove radi vođenja odgovarajućeg lijeka u obliku tekućine kroz putanju definiranu od strane navedenog prolaza (320; 321) do navedenog odvoda prolaza (324), i
A valve as claimed in any of the preceding claims, wherein the passageway of the valve member comprises, in the flow direction, a first part (320a; 321a) extending from the inlet (322) of the passageway towards the rotational axis, and a second part (320b; 321b) extending coaxially with the rotational axis from an radially inner end of the first part (320a; 321a) towards the channel outlet opening. 
Ventil prema bilo kojem od prethodnih Zahtjeva, gdje prolaz elementa ventila sadrži, promatrano u smjeru protoka, prvi dio (320a; 321a) koji se pruža od dovoda (322) prolaza prema osi rotacije i drugom dijelu (320b; 321b) koji se pruža koaksijalno s osi rotacije iz radijalno unutarnjeg kraja prvog dijela (320a; 321a) prema otvoru kanala odvoda.
A valve as claimed in any of the preceding claims, wherein the valve member (300) is prevented from rotating from one drug position to another drug position without passing a flushing position by the provision of rotational stop means (230, 340) limiting the rotational movement of the valve member (300). 
Ventil prema bilo kojem od prethodnih Zahtjeva, gdje je element (300) ventila spriječen da se rotacijom prevede iz pozicije za davanje jednog lijeka u poziciju za davanje drugog lijeka bez prethodnog prolaska kroz poziciju za ispiranje, zbog postojanja sredstva (230, 340) za zaustavljanje rotacije koje ograničava rotacijsko kretanje elementa (300) ventila.
The compound of Formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R1 is a hydrogen atom, and R2 is a hydrogen atom; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, gdje R1 je atom vodika, i R2 je atom vodika; ravna ili razgranata C1-C6 alkil grupa; ravna ili razgranata C1-C5 alkoksi grupa; ili ravna ili razgranata C1-C3 tioalkil grupa.
The compound of Formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) is any one of the following compounds: 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, gdje je spoj formule (I) bilo koji od sljedećih spojeva:
A compound of the following Formula (I'), or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a metabolic syndrome: in the formula, 
Spoj sljedeće formule (I'), ili njegova farmaceutski prihvatljiva sol, za primjenu u prevenciji ili liječenju metaboličkog sindroma: u formuli,
The compound of formula (I') of claim 12 for its use according to claim 12, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I') iz patentnog zahtjeva 12 za njegovu primjenu prema patentnom zahtjevu 12, gdje u formuli (I'), R1 je atom vodika, i R2 je atom vodika; hidroksi grupa; ravna ili razgranata C1-C6 alkil grupa; ravna ili razgranata C1-C5 alkoksi grupa; ili ravna ili razgranata C1-C3 tioalkil grupa.
The compound of formula (I') of claim 5 for its use according to claim 5, said compound being one or more of the following compounds: 
Spoj formule (I') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, pri čemu je navedeni spoj jedno ili više od sljedećih spojeva:
The compound of formula (I') of anyone of claims 5 to 8 for its use according to claim 9, wherein the diabetes is type 2 diabetes mellitus. 
Spoj formule (I') iz bilo kojeg od patentnih zahtjeva 5 do 8 za njegovu primjenu prema patentnom zahtjevu 9, gdje je dijabetes tip 2 dijabetes melitusa.
The compound of formula (I') of anyone of claims 5 to 8 for its use according to claim 5, wherein the metabolic syndrome is a complex disease of type 2 diabetes mellitus and obesity. 
Spoj formule (I') iz bilo kojeg od patentnih zahtjeva 5 do 8 za njegovu primjenu prema patentnom zahtjevu 5, gdje je metabolički sindrom kompleksna bolest dijabetes melitusa tipa 2 i pretilosti.
The compound of formula (I') of anyone of claims 12 to 15 for its use according to claim 12, wherein the inflammatory disease is one or more of rheumatoid arthritis; degenerative arthritis; and inflammatory diseases occurring from asthma, atopy, diabetes, or myocardial infarction. 
Spoj formule (I') iz bilo kojeg od patentnih zahtjeva 12 do 15 za njegovu primjenu prema patentnom zahtjevu 12, gdje je inflamatorna bolest jedna ili više od reumatoidnog artritisa; degenerativnog artritisa; i inflamatornih bolesti koje se javljaju kod astme, atopije, dijabetesa, ili infarkta miokarda.
R10aX4 [12] wherein R10a represents an optionally substituted acyl group; and X4 represents a halogen atom, or with a compound represented by the following formula [13]: 
aX4[12] gdje R10a predstavlja po izboru supstituiranu acil grupu; i X4 predstavlja atom halogena, ili sa spojem koji je predstavljen sljedećom formulom [13]: